here is the entire thing
here is a big group support
analystgroup.com initiates its coverage of HIV-VAC, Inc. (OTC BB: HIVC)
with a "Strong Buy" rating
HIV-VAC, Inc. (OTC BB: HIVC)
Recent Price: $0.34
52 Week Range: $0.125 to $3.125
Outstanding shares: 31.9 million
Float: 7.93 million
Market Cap: $10.8 million
2001 Projected Revenues: $4.375 million
2001 Projected Pre-Tax Loss: 1.468 millin
2002 Projected Revenues: $142.8 million
2002 Projected Pre-Tax Income: $63.1 million
Stock Rating: Strong Buy (Speculative)
12-24 Month Target Price: $4 to $5
Company Website: hivvac.com
Contact Person: Domenic Franco, 877-847-7719
INVESTMENT SUMMARY
- We rate HIV-VAC (OTCBB: HIVC) a "strong buy" for speculative investors.
HIVC is developing an HIV Intracellular Vaccine that provides the
necessary antibodies to combat HIV. It has the potential to moderate
disease progression in already infected persons as well as protect again
initial infection. The total number of people in the HIV high-risk
category comprises over 25% of the world's population. These are people
who have not yet contracted HIV, but will most likely do so during their
lifetime. This represents a potential marketplace of over 1.5 billion.
Add in the millions of HIV sufferers who could benefit from treatment for
their existing infection, the total potential marketplace for this vaccine
is staggering.
- The United Nations estimates that there are currently 33.6 million
people infected worldwide with the AIDS virus. The disease is spreading at
a rate of 10,000 people each day. It is estimated that the number of
people infected with the AIDS virus by the end of the year 2000 will be 55
million. HIV/AIDS caused 2.6 million deaths worldwide in 1999 and over
16.3 million cumulative number of deaths due to HIV/AIDS has been
recorded, according to World Health Organization. This is an epidemic of
global proportions. No country or economic group is immune. AIDS is
threatening to undo decades of development in Africa, and continues to
menace Russia, Eastern Europe and Asia. AIDS is already the
fourth-leading cause of death in the world and the leading cause in
sub-Saharan Africa. Convinced that the global spread of AIDS is reaching
catastrophic dimensions, the Clinton administration has formally
designated the disease for the first time as a threat to U.S. national
security that could topple foreign governments, touch off ethnic wars and
undo decades of work in building free-market democracies abroad.
- Current treatment consists of a standard drug "cocktails" that cost over
$10,000 per year, per person. To treat all America's HIV patients with
this regimen would cost over $5.4 billion. This treatment does not cure
the disease, if only holds it in check. Lives hand in the balance, and
America's health care system alone expects to add in excess of $6.2
billion in lifetime treatment costs alone to the nation's health care
bill. Sales of anti-HIV drugs increased to more than $3 billion last year
and could reach $6 billion in coming years worldwide.
- Many scientists, universities, institutions and organizations have been
working on a cure for the HIV virus for over 10 years. Most of these
studies have resulted in traditional approaches using old technology that
have shown little promise in truly providing a solution to this worldwide
epidemic. Dr. Skinner and his research team at the University of
Birmingham UK have developed a new approach to the HIV problem through a
technique called inactive intracellular sub-unit candidate preparation.
What makes this vaccine different, and more effective than other is the
mutating HIV virus cannot escape the immunization properties the Skinner
vaccine provides. This technology has already been proven in clinical
trials with herpes genitalis. The HIV vaccine has been satisfactorily
tested on animals, and the vaccine is believed to act as both a protective
agent against the HIV virus and has potential to modulate the progression
of HIV disease.
- When viruses infect cells, they make new virus particles within the cell
- the "intracellular" phase - and the newly formed virus particles leave
the cell and become free - the "extracellular" phase - before they goon to
infect new cells. During the intracellular phase, viruses make some
process but are not incorporated in the new viruses - the "regulatory"
protein and various intermediate proteins. The intracellular vaccine
NFU.Ac.HIV(JM) harvests all the proteins that are produced in the
intracellular phase, not just the ones contained in the virus articles,
and presents them in their natural configurations. The vaccine is
manufactured by detergent, formaldehyde and acetone treatment of HIV-1
infected cells; the newly formed viruses are stripped of their envelope
proteins, the virus particles are then discarded and the final preparation
is a mixture of virus and cell proteins. The combination of detergent,
formaldehyde and acetone, ensures that the vaccine is inactivated so that
it contains the important HIV-1 glycoproteins, core proteins, regulatory
and intermediate proteins but no infectious HIV-1 and it appears to be non
toxic. The method of preparation has the advantage that it can easily
accommodate different strains of HIV-1.
- OK, HIVC might have something that could be proven to be a major medical
breakthrough in history. Now question is that how much the stock should
be valued in the market place. As far as we know, only one public company
is doing something pretty like what HIVC does. It's VAXGEN, INC. (Nasdaq:
VXGN). VXGN is developing preventive vaccines for worldwide use against
HIV. Last year, VXGN has no sales with a loss over $24 million, but its
stock commands a market cap at $252 million. OTCBB stocks are often
valued at half of its peers on the NASADQ. Thus, this alone could give
HIVC a fair market valuation at $4 per share, not to mention HIVC's
vaccines which might be proven to be more effective than VXGN's. Wow!
Don't forget its potential EPS at $1.20 per share as projected by the
company in 2002. Shall we make another target price for the stock on the
basis of this analysis? No, we are not going to give! We stick with our
target price at $4 to $5! We are conservative, this is how our
subscribers could benefit from our style in this risky OTCBB market
filling with hype, bash, naked manipulation and short, not to mention all
kinds of emotion!
- Last March, the stock has been traded as high as $3.25 per share.
Since then, the stock has been substantially declining to the current
level. The stock has been traded extremely active in the past tens days.
A rumor is circulating now about a possible buyout by a major
pharmaceutical company. Also, we are hearing some major developments are
in the works and should be announced shortly. If one of them or both are
are true, the stock could be well over $5 before investors could grab any
shares.
- The company is projecting impressive growth rates for next two years,
but we believe they are reasonable considering the beginning of a pandemic
the likes which we have not seen in this century, and in the end will
probably never have seen in history. Recently, the Company has received
funding to begin the final stages of laboratory testing for its HIV/AIDS
vaccine that could prove to be both a preventative and therapeutic agent.
The trials will be conducted at the Russia Aids Centre and are expected to
be completed within 9 to 12 months. Phase I and II human trials will
commence once laboratory trials are completed. Further, the company
announced recently that it is working towards initiating human trials in
one or more African countries where HIV/AIDS has reached epidemic
proportions. These new trials in Africa would compliment trials currently
underway in Russia, and will also be undertaken in conjunction with a
major American University. We believe the vaccines have great chance to
be proven effective again HIV/AIDS. Hence, the stock is rated "strong
buy" for speculative investors.
THE COMPANY PROFILE
HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is
based on a new and very unique approach to neutralizing the AIDS virus.
Unlike many other AIDS vaccines under development, the Company believes
that the Skinner vaccine has the potential to be effective with the AIDS
virus' many mutant forms. This technology is based on a unique
intracellular vaccine technology proven in clinical trials with herpes
genitalis and pre-clinical research into cytomegalovirus and equine herpes
vaccines. This has been under development by Dr. Skinner and his team for
the past 10 years at the University of Birmingham, United Kingdom.
---------------------------------------------------------------
Copyright 2000, analystgroup.com. All rights reserved. Persons may
reprint or copy any portion of this publication, provided any reprint or
copy is accompanied by our web address (http://www.analystgroup.com).
analystgroup.com initiates its coverage of HIV-VAC, Inc. (OTC BB: HIVC)
with a "Strong Buy" rating
HIV-VAC, Inc. (OTC BB: HIVC)
Recent Price: $0.34
52 Week Range: $0.125 to $3.125
Outstanding shares: 31.9 million
Float: 7.93 million
Market Cap: $10.8 million
2001 Projected Revenues: $4.375 million
2001 Projected Pre-Tax Loss: 1.468 millin
2002 Projected Revenues: $142.8 million
2002 Projected Pre-Tax Income: $63.1 million
Stock Rating: Strong Buy (Speculative)
12-24 Month Target Price: $4 to $5
Company Website: hivvac.com
Contact Person: Domenic Franco, 877-847-7719
INVESTMENT SUMMARY
- We rate HIV-VAC (OTCBB: HIVC) a "strong buy" for speculative investors.
HIVC is developing an HIV Intracellular Vaccine that provides the
necessary antibodies to combat HIV. It has the potential to moderate
disease progression in already infected persons as well as protect again
initial infection. The total number of people in the HIV high-risk
category comprises over 25% of the world's population. These are people
who have not yet contracted HIV, but will most likely do so during their
lifetime. This represents a potential marketplace of over 1.5 billion.
Add in the millions of HIV sufferers who could benefit from treatment for
their existing infection, the total potential marketplace for this vaccine
is staggering.
- The United Nations estimates that there are currently 33.6 million
people infected worldwide with the AIDS virus. The disease is spreading at
a rate of 10,000 people each day. It is estimated that the number of
people infected with the AIDS virus by the end of the year 2000 will be 55
million. HIV/AIDS caused 2.6 million deaths worldwide in 1999 and over
16.3 million cumulative number of deaths due to HIV/AIDS has been
recorded, according to World Health Organization. This is an epidemic of
global proportions. No country or economic group is immune. AIDS is
threatening to undo decades of development in Africa, and continues to
menace Russia, Eastern Europe and Asia. AIDS is already the
fourth-leading cause of death in the world and the leading cause in
sub-Saharan Africa. Convinced that the global spread of AIDS is reaching
catastrophic dimensions, the Clinton administration has formally
designated the disease for the first time as a threat to U.S. national
security that could topple foreign governments, touch off ethnic wars and
undo decades of work in building free-market democracies abroad.
- Current treatment consists of a standard drug "cocktails" that cost over
$10,000 per year, per person. To treat all America's HIV patients with
this regimen would cost over $5.4 billion. This treatment does not cure
the disease, if only holds it in check. Lives hand in the balance, and
America's health care system alone expects to add in excess of $6.2
billion in lifetime treatment costs alone to the nation's health care
bill. Sales of anti-HIV drugs increased to more than $3 billion last year
and could reach $6 billion in coming years worldwide.
- Many scientists, universities, institutions and organizations have been
working on a cure for the HIV virus for over 10 years. Most of these
studies have resulted in traditional approaches using old technology that
have shown little promise in truly providing a solution to this worldwide
epidemic. Dr. Skinner and his research team at the University of
Birmingham UK have developed a new approach to the HIV problem through a
technique called inactive intracellular sub-unit candidate preparation.
What makes this vaccine different, and more effective than other is the
mutating HIV virus cannot escape the immunization properties the Skinner
vaccine provides. This technology has already been proven in clinical
trials with herpes genitalis. The HIV vaccine has been satisfactorily
tested on animals, and the vaccine is believed to act as both a protective
agent against the HIV virus and has potential to modulate the progression
of HIV disease.
- When viruses infect cells, they make new virus particles within the cell
- the "intracellular" phase - and the newly formed virus particles leave
the cell and become free - the "extracellular" phase - before they goon to
infect new cells. During the intracellular phase, viruses make some
process but are not incorporated in the new viruses - the "regulatory"
protein and various intermediate proteins. The intracellular vaccine
NFU.Ac.HIV(JM) harvests all the proteins that are produced in the
intracellular phase, not just the ones contained in the virus articles,
and presents them in their natural configurations. The vaccine is
manufactured by detergent, formaldehyde and acetone treatment of HIV-1
infected cells; the newly formed viruses are stripped of their envelope
proteins, the virus particles are then discarded and the final preparation
is a mixture of virus and cell proteins. The combination of detergent,
formaldehyde and acetone, ensures that the vaccine is inactivated so that
it contains the important HIV-1 glycoproteins, core proteins, regulatory
and intermediate proteins but no infectious HIV-1 and it appears to be non
toxic. The method of preparation has the advantage that it can easily
accommodate different strains of HIV-1.
- OK, HIVC might have something that could be proven to be a major medical
breakthrough in history. Now question is that how much the stock should
be valued in the market place. As far as we know, only one public company
is doing something pretty like what HIVC does. It's VAXGEN, INC. (Nasdaq:
VXGN). VXGN is developing preventive vaccines for worldwide use against
HIV. Last year, VXGN has no sales with a loss over $24 million, but its
stock commands a market cap at $252 million. OTCBB stocks are often
valued at half of its peers on the NASADQ. Thus, this alone could give
HIVC a fair market valuation at $4 per share, not to mention HIVC's
vaccines which might be proven to be more effective than VXGN's. Wow!
Don't forget its potential EPS at $1.20 per share as projected by the
company in 2002. Shall we make another target price for the stock on the
basis of this analysis? No, we are not going to give! We stick with our
target price at $4 to $5! We are conservative, this is how our
subscribers could benefit from our style in this risky OTCBB market
filling with hype, bash, naked manipulation and short, not to mention all
kinds of emotion!
- Last March, the stock has been traded as high as $3.25 per share.
Since then, the stock has been substantially declining to the current
level. The stock has been traded extremely active in the past tens days.
A rumor is circulating now about a possible buyout by a major
pharmaceutical company. Also, we are hearing some major developments are
in the works and should be announced shortly. If one of them or both are
are true, the stock could be well over $5 before investors could grab any
shares.
- The company is projecting impressive growth rates for next two years,
but we believe they are reasonable considering the beginning of a pandemic
the likes which we have not seen in this century, and in the end will
probably never have seen in history. Recently, the Company has received
funding to begin the final stages of laboratory testing for its HIV/AIDS
vaccine that could prove to be both a preventative and therapeutic agent.
The trials will be conducted at the Russia Aids Centre and are expected to
be completed within 9 to 12 months. Phase I and II human trials will
commence once laboratory trials are completed. Further, the company
announced recently that it is working towards initiating human trials in
one or more African countries where HIV/AIDS has reached epidemic
proportions. These new trials in Africa would compliment trials currently
underway in Russia, and will also be undertaken in conjunction with a
major American University. We believe the vaccines have great chance to
be proven effective again HIV/AIDS. Hence, the stock is rated "strong
buy" for speculative investors.
THE COMPANY PROFILE
HIV-VAC, Inc. is developing the Skinner HIV-VAC AIDS vaccine which is
based on a new and very unique approach to neutralizing the AIDS virus.
Unlike many other AIDS vaccines under development, the Company believes
that the Skinner vaccine has the potential to be effective with the AIDS
virus' many mutant forms. This technology is based on a unique
intracellular vaccine technology proven in clinical trials with herpes
genitalis and pre-clinical research into cytomegalovirus and equine herpes
vaccines. This has been under development by Dr. Skinner and his team for
the past 10 years at the University of Birmingham, United Kingdom.
---------------------------------------------------------------
Copyright 2000, analystgroup.com. All rights reserved. Persons may
reprint or copy any portion of this publication, provided any reprint or
copy is accompanied by our web address (http://www.analystgroup.com). |
